Akebia Therapeutics (AKBA) Liabilities and Shareholders Equity (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Liabilities and Shareholders Equity data on file, last reported at $362.5 million in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $362.5 million, up 16.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.4 billion (up 51.2% YoY), and the FY2025 annual result was $376.6 million, up 70.65% from the prior year.
• Liabilities and Shareholders Equity fell to $362.5 million in Q1 2026 per AKBA's latest filing, from $376.6 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $541.8 million in Q1 2022 and troughed at $207.1 million in Q3 2024.
• A 5-year average of $324.5 million and a median of $310.2 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity sank 52.12% in 2023, then soared 75.8% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $356.1 million in 2022, then slumped by 32.12% to $241.7 million in 2023, then slipped by 8.7% to $220.7 million in 2024, then surged by 70.65% to $376.6 million in 2025, then declined by 3.73% to $362.5 million in 2026.
• Business Quant data shows AKBA's Liabilities and Shareholders Equity at $362.5 million in Q1 2026, $376.6 million in Q4 2025, and $364.2 million in Q3 2025.